

Follow us on :



Contents

- [News and Commentary](#)
- [Media Releases](#)
- [Latest Research](#)
- [The Industry](#)
- [Leading Companies in the Industry](#)

AUSTRALIA BIOTECHNOLOGY AND PHARMACEUTICALS

9 February 2021

Acquisdata Podcast – Gary J Phillips, CEO Pharmaxis Ltd. (ASX: PXS), 29/4/2020 – COVID 19 response

Gary Phillips, Pharmaxis CEO, discusses ensuring continuity of supply of its products throughout the crisis, the timeframe for trials of its unique anti-fibrotic treatment for a rare bone cancer, broader impacts for biopharma research and trials, the opportunity for the global industry and the potential for PXS respiratory products in the clinical aftermath of COVID -19.

<https://youtu.be/hgJkNOBbsqc>

This Week's News

- **Morningstar - Dechra Pharmaceuticals In Tri-Solfen Deal, Ups Medical Ethics Stake - 8/2/2021**

Dechra Pharmaceuticals PLC on Monday said it has secured the rights to market Tri-Solfen in Australia and New Zealand.

For the complete story, see: https://www.morningstar.co.uk/uk/news/AN_1612773665015720700/dechra-pharmaceuticals-in-tri-solfen-deal-ups-medical-ethics-stake.aspx

- **Stockhead - MGC Pharma is to become the first medicinal cannabis company to list on the London Stock Exchange - 4/2/2021**

MGC Pharma to list on the London Stock Exchange, the first medicinal cannabis company to do so.

For the complete story, see: <https://stockhead.com.au/health/mgc-pharma-is-to-become-the-first-medicinal-cannabis-company-to-list-on-the-london-stock-exchange/>

- **Nasdaq - Australia to buy 10 mln additional doses of Pfizer COVID-19 vaccine - 3/2/2021**

Australia last week approved the Pfizer-BioNTech COVID-19 vaccine for use for people aged 16 years and older.

For the complete story, see: <https://www.nasdaq.com/articles/australia-to-buy-10-mln-additional-doses-of-pfizer-covid-19-vaccine-2021-02-03>

Other Stories

- UNSW Newsroom - Revolutionary eye drop trial starts for common eye diseases - 3/2/2021
- Xinhua - Australian PM reveals plan to vaccinate entire country by October - 1/2/2021
- 7NEWS.com.au - New heart condition drug listed on PBS - 31/1/2021
- Australian Government Department of Health - Greater access to life-changing medicine for Australians with ADHD - 30/1/2021
- The Guardian - Australia's coronavirus vaccine rollout hit as EU gives itself power to block exports -30/1/2021

Media Releases

- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) - Alterity announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials - 9/2/2021
- Bionomics Limited (ASX: BNO, OTCQX: BNOEF) - \$16 millions capital raise to progress BNC210 PTSD trial - 9/2/2021
- Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) - AZD0466 clinical DEP® program global expansion - 9/2/2021

NO.: 24934



AUSTRALIA BIOTECHNOLOGY AND PHARMACEUTICALS

- PolyNovo Limited (ASX: PNV) - PolyNovo enters Italy - 31/1/2021
- Kazia Therapeutics Limited (NASDAQ: KZIA) - Quarterly activities report and appendix C - 29/1/2021
- Mesoblast Limited (ASX: MSB; NASDAQ: MESO) - Appendix 4C Quarterly Activity Report - 29/1/2021

Latest Research

- Make it or break it: Plant AEPs on stage in biotechnology - By Mark A. Jackson, Linh T.T. Nguyen, Edward K. Gilding, Thomas Durek, David J. Craik

Overviews of Leading Companies

Acrux Limited (ASX: ACR)
 Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE)
 Benitec Biopharma Limited (ASX: BLT)
 Bionomics Limited (ASX: BNO, OTCQX: BNOEF)
 Clinuvel Pharmaceuticals Limited (ASX: CUV)
 CSL Limited (ASX: CSL)
 Genera Biosystems Limited
 IDT Australia Limited (ASX: IDT)
 Immutep Limited (ASX: IMM, NASDAQ: IMMP)
 Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA)
 Mayne Pharma Group Limited (ASX: MYX)
 Medical Developments International Limited (ASX: MVP)
 Medlab Clinical Limited (ASX: MDC)
 Mesoblast Limited (ASX: MSB; NASDAQ: MESO)
 MMJ Group Holdings Limited (ASX: MMJ)
 Monash IVF Group (ASX: MVF)
 Neuren Pharmaceuticals Limited (ASX: NEU)
 Palla Pharma Limited (ASX: PAL)
 Pharmaxis Limited (ASX: PXS)
 PolyNovo Limited (ASX: PNV)
 Sirtex Medical Limited
 Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY)
 Viralytics Limited (NYSE: MRK)
 Vita Life Sciences Limited (ASX: VLS)

Senior Associate: Joseph Hang Ellision

Are you MIFID II ready? You might like to talk to Acquisdata about our Bespoke Research offering.
www.acquisdata.com/bespoke-research #

Looking for
 more in-depth
 research ?



We also produce in-depth reports on a range of newly emerging market sectors.
 See our sister company's website at www.macrosourcemedia.com

Topics include: Deep Sea Mining, Fintech, Robotics, Smart City Technologies, High-Tech Shipping, UAV (drones), Internet of Things, Cybersecurity, Artificial Intelligence Software and more.

NO.: 24934



AUSTRALIA BIOTECHNOLOGY AND PHARMACEUTICALS

Acquisdata InView

Latest Version

Acquisdata InView - BioPharma - June 2019

<https://www.docdroid.net/5PeNs6Y/acquisdata-inview-biopharma-dr-peter-french-june-2019.pdf>

Dr Peter French, Biotechnology Consultant, speaks with Acquisdata's Fiona Fox about superbugs, bacteriophage and CRISPR gene-editing technology and biopharma companies working in this space.

View the playlist on Acquisdata's YouTube channel here:

<https://www.youtube.com/playlist?list=PLLht7jPps2v2runHsQivr-ANhIKQ9Zy-v>

Earlier Biopharma InViews:

Acquisdata InView - Biopharma - August 2018 (Topic: cancer diagnostics)

http://www.reportaldata.com/video/InView_BioPharma_201809/Acquisdata%20InView%20-%20Bio-Pharma%20-%20Dr%20Peter%20French%20August%202018.pdf

View the playlist here: <https://www.youtube.com/playlist?list=PLLht7jPps2v1i9AyH4yJbFsATaAq8eYNx>

ABOUT InView

Learn from industry experts with Acquisdata InView. The latest addition to the Acquisdata suite of information products, Acquisdata InView features interviews with experts across a range of industries on topical issues.

Acquisdata is excited to connect with experts from across the world for InView. InView also opens the way for more in-depth Executive SnapShot interviews with company executives for their perspective on what's happening in their company and industry.

Coming up next will be Defence Expert, Rowan Moffitt, to give his view on developments in the defence and armaments industry for Acquisdata InView - Defence.

Acquisdata InView is available via the Acquisdata website, Reuters Eikon and Acquisdata's extensive network of distributors.

Industry SnapShots

Published by **Acquisdata Pty Ltd**

A.C.N. 147 825 536

ISSN 2203-2738 (Electronic)

©Acquisdata Pty Ltd 2021

www.acquisdata.com

Disclaimer of Warranties and Liability

Due to the number of sources from which the information and services on the Acquisdata Pty Ltd Service are obtained, and the inherent hazards of electronic distribution, there may be delays, omissions or inaccuracies in such information and services. Acquisdata Pty Ltd and its affiliates, agents, sales representatives, distributors, and licensors cannot and do not warrant the accuracy, completeness, currentness, merchant ability or fitness for a particular purpose of the information or services available through the Acquisdata Pty Ltd service. In no event will Acquisdata Pty Ltd, its affiliates, agents, sales representatives, distributors or licensors be liable to licensee or anyone else for any loss or injury caused in whole or part by contingencies beyond its control in procuring, compiling, interpreting, editing, writing, reporting or delivering any information or services through the Acquisdata Pty Ltd Service. In no event will Acquisdata Pty Ltd or its affiliates, agents, sales representatives, distributors or licensors be liable to licensee or anyone else for any decision made or action taken by licensee in reliance upon such information or services or for any consequential, special or similar damages, even if advised of the possibility of such damages. licensee agrees that the liability of Acquisdata Pty Ltd, its affiliates, agents, sales representatives, distributors and licensors, if any, arising out of any kind of legal claim (whether in contract, tort or otherwise) in any way connected with the Acquisdata Pty Ltd service shall not exceed the amount licensee paid for the use of the Acquisdata Pty Ltd service in the twelve (12) months immediately preceding the event giving rise to such claim.